Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Pediatr Adolesc Med ; 154(12): 1214-8, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11115305

ABSTRACT

OBJECTIVE: To determine the safety and efficacy of glycopyrrolate in the treatment of developmentally disabled children with sialorrhea. DESIGN: Placebo-controlled, double-blind, crossover dose-ranging study. SETTING: Outpatient facilities in 2 pediatric hospitals. PATIENTS: Thirty-nine children with both developmental disabilities and excessive and bothersome sialorrhea. MAIN OUTCOME MEASURES: Parent and investigator evaluation of change in sialorrhea and adverse effects. RESULTS: Glycopyrrolate in doses of 0.10 mg/kg per dose is effective at controlling sialorrhea. Even at low doses, 20% of children may exhibit adverse effects severe enough to require discontinuation. CONCLUSIONS: Glycopyrrolate is effective in the control of excessive sialorrhea in children with developmental disabilities. Approximately 20% of children given glycopyrrolate may experience substantial adverse effects, enough to require discontinuation of medication. Arch Pediatr Adolesc Med. 2000;154:1214-1218.


Subject(s)
Developmental Disabilities/complications , Glycopyrrolate/therapeutic use , Muscarinic Antagonists/therapeutic use , Sialorrhea/complications , Sialorrhea/drug therapy , Adolescent , Adult , Child , Child, Preschool , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Glycopyrrolate/adverse effects , Humans , Muscarinic Antagonists/adverse effects
2.
J Spinal Disord ; 12(3): 197-205, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10382772

ABSTRACT

A retrospective review of 107 patients with cerebral palsy who had undergone a posterior spinal fusion with unit rod instrumentation by the same two surgeons was done to determine what factors cause complications that lead to delayed recovery time and a longer than average hospital stay. The operative risk score was developed with scores for the child's ability to walk and talk, oral feeding ability, cognitive ability, and medical problems within the year prior to surgery. Operative risk score is primarily a measure of degree of neurologic involvement. The postoperative complication score (POCS) is a combined measure of all postoperative complications including factors for prolonged intubation, intensive care unit stay, hospital stay, and delayed feeding. The mean age at surgery was 14.3 years. The mean weight was 29.5 kg, with 89 of 107 patients below the fifth percentile for weight compared with age. The mean degree of spinal deformity was 75.2 degrees (range 43-120 degrees ). The mean weight for age was -1.96 SD below the normal. The mean operative time was 4.3 h, with estimated blood loss of 1.2 blood volumes. The mean length of hospitalization was 23 days 2 h, with 5 days 2 h in the intensive care unit. The operative risk score and weight for chronological age below the fifth percentile showed statistical significance (p = 0.05) in regard to increased POCS. The weight for height-age and deficient total lymphocyte count, both factors that measure nutritional status, showed no statistical significance (p > 0.05) compared with POCS. Curves with deformity of >70 degrees had statistically significant high POCS (p = 0.03). Complications for patients having a posterior and an anterior surgery versus those who had a posterior fusion alone were not statistically different (p > 0.05). The factors that led to a greater rate of complications were the severity of neurologic involvement, severity of recent history of significant medical problems, and severity of scoliosis.


Subject(s)
Cerebral Palsy/complications , Postoperative Complications/etiology , Preoperative Care , Spinal Fusion/adverse effects , Adolescent , Adult , Cerebral Palsy/surgery , Child , Female , Humans , Male , Nutritional Status , Retrospective Studies , Risk Factors
3.
Clin Pediatr (Phila) ; 37(8): 485-90, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9729704

ABSTRACT

Fifty-four parents/caretakers of children with cerebral palsy were surveyed regarding their use of antisialorrheic medication for excessive drooling. Glycopyrrolate was used by 37 of 41 respondents, with significant improvement in drooling noted in the vast majority (95%) of cases as indicated by a five-point rating scale. Side effects (dry mouth, thick secretions, urinary retention, or flushing) surfaced in almost half (44%) of the patients but necessitated discontinuation of pharmacologic treatment in less than a third. While larger clinical studies are needed, our preliminary data indicate a trial of glycopyrrolate should be considered in children with cerebral palsy where drooling is a significant problem.


Subject(s)
Cerebral Palsy/physiopathology , Glycopyrrolate/administration & dosage , Sialorrhea/etiology , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Glycopyrrolate/adverse effects , Humans , Male , Sialorrhea/drug therapy , Sialorrhea/prevention & control
4.
J Pediatr ; 125(5 Pt 1): 750-2, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7965428

ABSTRACT

Helicobacter pylori infection was identified in five patients with profound neurologic impairment who were undergoing evaluation for gastrointestinal symptoms, and it was subsequently identified in 7 of 61 patients with symptoms whose condition was evaluated prospectively. Institutionalized patients were at greater risk of infection. Treatment of H. pylori infection resulted in symptomatic improvement for the majority of patients.


Subject(s)
Gastritis/microbiology , Helicobacter Infections/complications , Helicobacter pylori , Nervous System Diseases/complications , Pyloric Antrum/microbiology , Adolescent , Child , Child, Preschool , Endoscopy, Gastrointestinal , Follow-Up Studies , Gastritis/diagnosis , Gastritis/surgery , Gastrostomy , Humans , Middle Aged , Mucous Membrane/microbiology , Prospective Studies , Retrospective Studies , Severity of Illness Index , Time Factors
5.
Clin Pediatr (Phila) ; 32(9): 535-41, 1993 Sep.
Article in English | MEDLINE | ID: mdl-8258206

ABSTRACT

Shortly after being weaned off the respirator, 43 infants with severe chronic bronchopulmonary dysplasia (BPD) were transferred from an intensive-care nursery at a teaching hospital to an affiliated children's rehabilitation hospital in a program that included special staff instruction. Morbidity, measured by rate of transfer back to the acute-care hospital, was lower than in a comparison group of 15 infants treated for severe BPD during the previous two years. Average length of stay was significantly shortened and an average of $60,000 per patient was saved. Using a rehabilitation hospital as a step-down unit shifts the emphasis from acute needs to chronic and developmental needs and from intensive monitoring and nursing care to care given at home by parents with nursing assistance.


Subject(s)
Bronchopulmonary Dysplasia/rehabilitation , Intensive Care Units, Neonatal/statistics & numerical data , Patient Transfer/statistics & numerical data , Rehabilitation Centers/statistics & numerical data , Bronchopulmonary Dysplasia/economics , Bronchopulmonary Dysplasia/epidemiology , Chronic Disease , Female , Hospitals, University/statistics & numerical data , Humans , Infant , Infant, Newborn , Length of Stay/statistics & numerical data , Male , Morbidity , Philadelphia , Progressive Patient Care
6.
Pediatrics ; 91(3): 624-7, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8441570

ABSTRACT

Sedating children safely and effectively for minor laceration repair is a well-recognized clinical problem. A randomized, double-blind, and controlled study was conducted to evaluate the efficacy of intranasal midazolam for reducing stress during the suturing of lacerations in preschool children. Fifty-nine children with simple lacerations that required suturing were randomly assigned to one of three groups. Group 1 received intranasal midazolam, 0.4 mg/kg, prior to suturing. Group 2 received an equivalent volume of normal saline intranasally prior to suturing as a placebo. Group 3 was the control group and received no intervention prior to suturing. Heart rate, respiratory rate, blood pressure, and pulse oximetry were monitored at 5-minute intervals throughout the procedure. Subjective variables were also measured at 5-minute intervals and included a cry score, a motion score, and a struggle score. Parent satisfaction was measured via a short telephone interview the following day. There were no significant differences in outcome between the placebo group and the control group. Their results were pooled and compared with the results for the midazolam group. The midazolam group showed significant reductions for mean heart rate, maximum heart rate, and maximum systolic blood pressure when compared with the placebo/control group. Scores for two of the three subjective variables, cry and struggle, were significantly reduced for the midazolam group. The papoose board was considered unnecessary in retrospect for more than half of patients in the midazolam group compared with only one fifth of patients in the placebo/control group.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Anxiety/prevention & control , Conscious Sedation , Midazolam/therapeutic use , Skin/injuries , Stress, Psychological/prevention & control , Administration, Intranasal , Child, Preschool , Double-Blind Method , Humans , Infant , Midazolam/administration & dosage , Pain/prevention & control , Treatment Outcome , Wounds and Injuries/surgery
7.
Clin Pediatr (Phila) ; 20(2): 127-31, 1981 Feb.
Article in English | MEDLINE | ID: mdl-7006881

ABSTRACT

An outbreak of shigellosis is described in an intermediate care hospital for children, where routine isolation procedures failed to halt the outbreak. Two weeks after the appearance of the first case, small numbers of patients became symptomatic with fever and diarrhea, but remained culture-negative. One week later, two patients with positive cultures were identified, with many other symptomatic patients having negative cultures. Twenty-five days after identification of the first case, there were fourteen cases identified with shigellosis and many more symptomatic patients. It was at that time that hospital-wide measures of infection control were instituted, and treatment of all patients, infected and uninfected, was initiated with trimethoprim-sulfamethoxazole (TMP-SMX). No new cases of shigellosis were diagnosed after initiation of treatment, and symptoms abated within 72 hours.


Subject(s)
Cross Infection/drug therapy , Disease Outbreaks , Dysentery, Bacillary/drug therapy , Drug Combinations , Drug Resistance, Microbial , Female , Humans , Infant , Male , Shigella sonnei , Sulfamethoxazole/therapeutic use , Trimethoprim/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...